mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.089 |
0.04 |
mRNA |
Sorafenib |
CCLE |
pan-cancer |
AAC |
0.093 |
0.04 |
mRNA |
BRD-K92856060 |
CTRPv2 |
pan-cancer |
AAC |
-0.091 |
0.04 |
mRNA |
Nutlin-3 |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.04 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.082 |
0.04 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.04 |
mRNA |
BRD-K03536150 |
CTRPv2 |
pan-cancer |
AAC |
-0.093 |
0.05 |
mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
0.087 |
0.05 |
mRNA |
VAF-347 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.05 |
mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.05 |